Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story

Article excerpt

A randomized trial of Grail's Galleri multi-cancer early detection test, involving 143,000 English adults aged 50-77, produced disappointing headline results, showing no mortality benefit over standard care. Yet an oncologist argues the negative finding obscures important nuances: the test identified cancers earlier and in more treatable stages, and the trial may have been underpowered or too short to capture survival gains. The stakes are substantial: if multi-cancer blood tests can genuinely shift cancer detection upstream, they could reshape screening practice; if they can't deliver on that promise, they represent expensive false hope.